Ladenburg Thalmann downgrades Traws Pharma to Neutral
Ladenburg Thalmann analyst Kevin DeGeeter downgraded Traws Pharma from Buy to Neutral, revising the investment stance on the NASDAQ-listed company.
*this image is generated using AI for illustrative purposes only.
Ladenburg Thalmann analyst Kevin DeGeeter has downgraded Traws Pharma from Buy to Neutral, adjusting the investment outlook for the NASDAQ-listed firm. The rating revision signals a shift in the analyst's expectations regarding the company's near-term performance potential.
Analyst Rating Change
The downgrade from Buy to Neutral was issued by Kevin DeGeeter, an analyst at Ladenburg Thalmann. This action modifies the previous bullish stance on the stock to a more neutral position.
| Company | Previous Rating | New Rating |
|---|---|---|
| Traws Pharma | Buy | Neutral |
Traws Pharma trades on the NASDAQ under the ticker symbol TRAW.
What specific factors prompted Ladenburg Thalmann to revise its outlook on Traws Pharma?
How might this downgrade impact investor sentiment and trading volume for TRAW in the near term?
Could other analysts follow suit with similar rating adjustments for Traws Pharma?
19
Access Market Heat-map & Insights 
Create, Save & Share your Screener 
Use 200+ Screening Filters 
